CClinicalTrials.gg
WithdrawnNCT02558309Updated Jan 12, 2017

Optic Nerve Head Quantification While Reducing Elevated Intracranial Pressure

An observational study in Intraocular Pressure and Intracranial Hypertension, sponsored by NYU Langone Health. Withdrawn. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-12.

Sponsored by NYU Langone Health · Observational

Why this study was withdrawn
The Primary Investigator is no longer with UPMC. No patients have been enrolled.
Study type
Observational
Model
Case-only
Time perspective
Prospective
Enrollment
0
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this study is to examine in-vivo the effect of intraocular (IOP) and intracranial pressures (ICP) on the optic nerve head (ONH). The effect of ICP on eye health has been an area of concrete research effort in recent years. The ability to acquire non-invasive and highly detailed information on both the eye and the brain using technologies such as magnetic resonance imaging (MRI) and optical coherence tomography (OCT) have paved the way to assess non-invasively the effect of ICP in-vivo. In this study, we will quantify the structural changes in the ONH in subjects with elevated ICP while they are treated to reduce the elevated pressure. This process will occur in a stepwise fashion over a period of time determined by the clinical treatment plans. We will apply controlled pressures to the eye during each step of ICP lowering while OCT images are obtained.

Read the detailed description

Objective:

The goal of this study is to examine in-vivo the effect of intraocular (IOP) and intracranial pressures (ICP) on the optic nerve head (ONH).

Specific Aims:

In this study, the investigators will quantify the structural changes in the ONH in subjects with elevated ICP while they are treated to reduce the elevated pressure. This process will occur in a stepwise fashion over a period of time determined by the clinical treatment plans. The investigators will apply controlled pressures to the eye during each step of ICP lowering while OCT images are obtained.

Background:

The effect of ICP on eye health has been an area of concrete research effort in recent years. The ability to acquire non-invasive and highly detailed information on both the eye and the brain using technologies such as magnetic resonance imaging (MRI) and optical coherence tomography (OCT) have paved the way to assess non-invasively the effect of ICP in-vivo.

The ONH separates two pressurized compartments: the eyeball and the central nervous system. Situations in which ICP is elevated are often associated with papilledema, though the magnitude and the rate of change in ONH elevation in response to increased ICP or the reduction in ONH elevation in response to ICP treatments are yet to be determined. On the opposite side, glaucoma is a leading cause of blindness where elevated IOP is the leading risk factor, with clinical evidence suggesting the presence of ICP below the normal level in these subjects. The impaired balance between IOP and ICP leads to the deformation of the ONH, which triggers strangulation of the retinal ganglion cell axons when trespassing through the lamina cribrosa within the ONH on their way from the eye to the brain, leading to gradual axonal loss and irreversible visual impairment.

Significance:

Little is known about how the interaction of IOP and ICP pressure changes affect the macrostructure and microstructure of the optic nerve head structure. This information has a significant impact both for neurosurgical conditions with elevated ICP along with ocular conditions such as glaucoma and papilledema. The ability to gauge non-invasively changes in ICP will have a tremendous impact on neurosurgical management as it eliminates the need of longitudinal invasive measurements of ICP. The study will also improve the investigator's understanding of the pathophysiologic processes that lead to development of glaucoma as well as the response to treatment for subjects with papilledema. A better understanding of these processes will ultimately lead to improved detection and management of these conditions and a better understanding of ocular bio-mechanics.

02

Conditions studied

  • Intraocular Pressure
  • Intracranial Hypertension
03

In context

Intracranial Hypertension

185 studies on the registry are indexed under Intracranial Hypertension; 45 are open to participants now.

Browse Intracranial Hypertension studies →

Lead sponsor

NYU Langone Health is the lead sponsor of 1,391 studies on the registry; 254 are open to participants now.

Of its 227 completed or terminated interventional studies of FDA-regulated products, 191 (84%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

Subjects who are scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened.

Inclusion criteria

  • Age 18 and older.
  • Patients with an external ventricular drain (EVD).
  • Normally appearing eye as determined during the screening clinical examination.

Exclusion criteria

Exclusion Criteria:

  • History of intraocular surgery or ocular trauma (with the exception of laser procedures or uneventful cataract surgery more than 1 year from enrollment date).
  • Ocular disorders that could affect retinal function such as retinal detachment, diabetic retinopathy, Macular degeneration.
  • Neurological \& Non-Glaucomatous causes for Visual Field damage.
05

Study design

Observational model
Case-only
Time perspective
Prospective
Enrollment
0 participants (actual)
Patient registry
No

Groups and cohorts

  • Intracranial Pressure Reduction

    Subjects scheduled to undergo gradual, step-wise reduction of Intracranial Pressure (ICP) will be screened. * The Glasgow Coma Scale will be administered to ascertain the cognitive ability of the participant. * A slit lamp examination and indirect ophthalmoscopy will be performed. Experimental: * The subject's eye will be held open with an eye speculum during the exam. * Another eye exam, which includes a slit lamp examination and indirect ophthalmoscopy, will be performed. * Intraocular Pressure will be measured. * An Optic Coherence Tomography (OCT) will be performed. * At each step along the process of ICP reduction, the eye exam, IOP \& OCT will be performed. Optional: * The Ophthalmology study team will raise the IOP using an Ophthlmodynanometer. It will be raised to 20 mmHg and 40 mmHg while OCT scans are obtained. * OCT scans will be taken at pre-manipulation, 20mmHg, 40mmHg, and post-manipulation at each step of the ICP lowering procedure.

06

What researchers measure

Primary outcomes

  1. Optic Nerve Head

    The optic nerve head (ONH) structures will be evaluated for tissue deformation. The association between the structural findings in the optic nerve head region and intracranial and intraocular pressures will be evaluated.

    Time frame: 1 Week

07

Study locations

No study locations are listed for this record.

08

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Jan 12, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02558309
Lead sponsor
NYU Langone Health
Responsible party
Sponsor
First posted
Sep 23, 2015
Start date
Oct 2015
Primary completion
Oct 2016 (estimated)
Completion
Oct 2017 (estimated)
Last update
Jan 12, 2017

Study contacts

Gadi Wollstein, MD
principal investigator · University of Pittsburgh Medical Center

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion